These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29523466)

  • 1. Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction.
    Wilkins B; Hullikunte S; Simmonds M; Sasse A; Larsen P; Harding SA
    Heart Lung Circ; 2019 Feb; 28(2):257-262. PubMed ID: 29523466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
    Bruggmann C; Iglesias JF; Gex-Fabry M; Fesselet R; Vogt P; Sadeghipour F; Voirol P
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):105-115. PubMed ID: 31300969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.
    Pereira M; Araújo C; Dias P; Lunet N; Subirana I; Marrugat J; Capewell S; Bennett K; Azevedo A
    Eur J Prev Cardiol; 2014 Nov; 21(11):1401-8. PubMed ID: 23787795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is quality improvement sustainable? Findings of the American College of Cardiology's Guidelines Applied in Practice.
    Olomu AB; Stommel M; Holmes-Rovner MM; Prieto AR; Corser WD; Gourineni V; Eagle KA
    Int J Qual Health Care; 2014 Jun; 26(3):215-22. PubMed ID: 24815063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non-Aboriginal patients admitted to Western Australian hospitals.
    Gausia K; Katzenellenbogen JM; Sanfilippo FM; Knuiman MW; Thompson PL; Hobbs MS; Thompson SC
    Intern Med J; 2014 Apr; 44(4):353-61. PubMed ID: 24528930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018.
    Lõiveke P; Marandi T; Ainla T; Fischer K; Eha J
    BMC Cardiovasc Disord; 2021 Oct; 21(1):505. PubMed ID: 34670499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures.
    Allen LA; Fonarow GC; Liang L; Schulte PJ; Masoudi FA; Rumsfeld JS; Ho PM; Eapen ZJ; Hernandez AF; Heidenreich PA; Bhatt DL; Peterson ED; Krumholz HM;
    Circulation; 2015 Oct; 132(14):1347-53. PubMed ID: 26316616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence.
    Bauer T; Gitt AK; Jünger C; Zahn R; Koeth O; Towae F; Schwarz AK; Bestehorn K; Senges J; Zeymer U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):576-81. PubMed ID: 20351550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.
    Ergatoudes C; Thunström E; Rosengren A; Björck L; Bengtsson Boström K; Falk K; Fu M
    BMC Cardiovasc Disord; 2016 Nov; 16(1):226. PubMed ID: 27855640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving patient adherence to secondary prevention medications 6 months after an acute coronary syndrome: observational cohort study.
    Brieger D; Chow C; Gullick J; Hyun K; D'Souza M; Briffa T;
    Intern Med J; 2018 May; 48(5):541-549. PubMed ID: 29345403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice.
    Kassab YW; Hassan Y; Aziz NA; Akram H; Ismail O
    J Eval Clin Pract; 2013 Aug; 19(4):658-63. PubMed ID: 22845427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH; Pereg D; Lishner M; Elis A
    Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
.
    Kang HB; Choi M; Yoon SG; Cho YS; Je NK
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of adherence to evidence-based therapy after acute myocardial infarction.
    Hamood H; Hamood R; Green MS; Almog R
    Eur J Prev Cardiol; 2016 Jun; 23(9):975-85. PubMed ID: 26198723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors.
    Gunnell AS; Hung J; Knuiman MW; Nedkoff L; Gillies M; Geelhoed E; Hobbs MS; Katzenellenbogen JM; Rankin JM; Ortiz M; Briffa TG; Sanfilippo FM
    Cardiovasc Ther; 2016 Dec; 34(6):423-430. PubMed ID: 27489053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.